WA Innovators of the Year: 2025 Wesfarmers Wellbeing Platinum Award finalists

Advanced therapeutic model for treatment-resistant post-traumatic stress disorder (PTSD) 

Emyria operates Australia’s first psychiatrist-led, evidence-based medication-assisted therapy program for post-traumatic stress disorder (PTSD), in purpose-built Empax Centres. Designed for severe, treatment-resistant PTSD, the program combines potent medication, intensive psychotherapeutic support, advanced in-room monitoring, and AI-generated music within a trauma-informed, multidisciplinary care model. 

Emyria is the only service nationally with a major agreement with Medibank Private, enabling broader patient access. Underpinned by rigorous clinical governance and continuous real-world data collection, the program not only aims to transform lives but also generates critical insights to guide safe, scalable adoption of innovative mental health treatments, positioning Western Australia as a leader in psychiatric care. 

Rural and remote healthcare access by Fly2 Health Group 

Fly2Health is a WA-founded organisation revolutionising access to allied health services in regional and remote Australia. Using light aircraft, Fly2Health transports clinicians directly to over 100 communities, including remote Aboriginal communities, overcoming barriers of distance, cost, and infrastructure. 

With a team of 140+ professionals, services span physiotherapy, occupational therapy, speech pathology, psychology, and more, delivered to clients and patients at a community-equivalent standard. The company’s model integrates co-designed service delivery and continuous feedback to ensure culturally safe, high-quality care. Fly2Health’s mission is simple: bring equal access to all Australians, no matter where their location is 

Innovative pharmacogenomic genetic test platform with analytic and reporting software 

Gene S is a Perth-based biotechnology company specialising in innovative pharmacogenomic (PGx) solutions that use genetic insights to guide safer, more effective prescribing. Our mission is to transform healthcare by enabling truly personalised medicine, reducing trial-and-error prescribing, and improving patient outcomes.  

We have successfully developed and validated the RosaMind PGx kit for mental health medications and are now expanding into pain management with the RosaPAIN test. We combine next-generation sequencing with our proprietary analysis software, turning complex genetic data into clear, practical reports for clinicians. Collaborating with clinicians, laboratories, researchers and patients, Gene S solutions meet the needs of all enabling personalised health care and improved patient outcomes. 

Australia’s first digital surgery support program for endometriosis 

Matilda is a co-designed, clinician-led digital program delivering compassionate, evidence-based care around endometriosis surgery. Co-founded by pelvic health physiotherapist Joanna Morris and Dr Kevin Wernli (PhD), it offers an 8-week pathway (4-week prehab + 4-week rehab, with 12 months’ access) to help people prepare, recover, and feel supported.  

Expert micro-lessons from pelvic physios, dietitians, psychologists and more are combined with movement, mindfulness, nutrition guidance, weekly touchpoints, and a moderated peer community. Built with lived experience and clinicians, Matilda integrates seamlessly into surgical pathways and provides tailored outcome measures back to gynaecologists, enhancing clinical care.  

With research partnerships underway, it is advancing towards precision medicine and expanding into other under-researched and under-supported surgical conditions.